IDEAS home Printed from https://ideas.repec.org/a/epw/ejmed0/v2y2020i5id40482.html

Nanomedicine and Immunotherapy for Cancers

Author

Listed:
  • A. A. Navas
  • N. Doreswamy
  • P. J. Joseph Francis

Abstract

Nanomedicine contributes to cancer therapeutics in several ways, harnessing some of the remarkable properties of nanomaterials to target tumor cells with increasing specificity. Nano-scale therapeutic strategies enable the simultaneous transport of hydrophilic and hydrophobic drugs across physical and physiological barriers like the blood-brain barrier. Alternative routes of drug administration, such as the intranasal route, have become viable, with more promising therapies for highly lethal tumors like glioblastomas. Cancer nanomedicine allows increased solubility and bioavailability of anti-cancer drugs, reducing their toxicity. Multi-drug delivery systems such as dendrimers, noble metal nanoparticle drug delivery systems, nanoparticle-based theranostics, and nano-biomarkers may well bring about a sea change in cancer therapeutics. This review presents an overview of the scope of cancer nanomedicine, including immunotherapy for cancer.

Suggested Citation

  • A. A. Navas & N. Doreswamy & P. J. Joseph Francis, 2020. "Nanomedicine and Immunotherapy for Cancers," European Journal of Medical and Health Sciences, European Open Science, vol. 2(5), September.
    • Handle: RePEc:epw:ejmed0:v:2:y:2020:i:5:id:40482
    DOI: 10.24018/ejmed.2020.2.5.482
    as

    Download full text from publisher

    File URL: https://eu-opensci.org/index.php/ejmed/article/view/40482
    File Function: Abstract page
    Download Restriction: no
    File URL: https://eu-opensci.org/index.php/ejmed/article/download/40482/9037
    File Function: Full text
    Download Restriction: no
    File URL: https://libkey.io/10.24018/ejmed.2020.2.5.482?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Caroline Robert, 2020. "A decade of immune-checkpoint inhibitors in cancer therapy," Nature Communications, Nature, vol. 11(1), pages 1-3, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Qianqian Ming & Daniel Antfolk & David A. Price & Anna Manturova & Elliot Medina & Srishti Singh & Charlotte Mason & Timothy H. Tran & Keiran S. M. Smalley & Daisy W. Leung & Vincent C. Luca, 2024. "Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab," Nature Communications, Nature, vol. 15(1), pages 1-11, December.
    2. Saeed Daneshmandi & Qi Yan & Eduardo Cortes Gomez & Jee Eun Choi & Eriko Katsuta & Ehsan Gharib & Prashant K. Singh & Richard M. Higashi & Andrew N. Lane & Teresa W-M. Fan & Jianmin Wang & Elizabeth A, 2026. "6-Phosphogluconate dehydrogenase promotes mitochondrial fusion and immune suppression in tumor-associated monocytic suppressor cells," Nature Communications, Nature, vol. 17(1), pages 1-19, December.
    3. Nandini Pal Basak & Kowshik Jaganathan & Biswajit Das & Oliyarasi Muthusamy & Rajashekar M & Ritu Malhotra & Amit Samal & Moumita Nath & Ganesh MS & Amritha Prabha Shankar & Prakash BV & Vijay Pillai , 2024. "Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    4. Yue Wang & Shi-Kun Zhou & Yan Wang & Zi-Dong Lu & Yue Zhang & Cong-Fei Xu & Jun Wang, 2023. "Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    5. Avishai Maliah & Nadine Santana-Magal & Shivang Parikh & Sagi Gordon & Keren Reshef & Yuval Sade & Aseel Khateeb & Alon Richter & Amit Gutwillig & Roma Parikh & Tamar Golan & Matan Krissi & Manho Na &, 2024. "Crosslinking of Ly6a metabolically reprograms CD8 T cells for cancer immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    6. Changfa Shu & Jianfeng Li & Jin Rui & Dacheng Fan & Qiankun Niu & Ruiyang Bai & Danielle Cicka & Sean Doyle & Alafate Wahafu & Xi Zheng & Yuhong Du & Andrey A. Ivanov & Deon B. Doxie & Kavita M. Dhoda, 2025. "Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer," Nature Communications, Nature, vol. 16(1), pages 1-18, December.
    7. Caihua Zhang & Kang Li & Hongzhang Zhu & Maosheng Cheng & Shuang Chen & Rongsong Ling & Cheng Wang & Demeng Chen, 2024. "ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration," Nature Communications, Nature, vol. 15(1), pages 1-23, December.
    8. Ignacio Heras-Murillo & Diego Mañanes & Pablo Munné & Vanessa Núñez & Jessica Herrera & Mauro Catalá-Montoro & Maite Alvarez & Miguel A. del Pozo & Ignacio Melero & Stefanie K. Wculek & David Sancho, 2025. "Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse," Nature Communications, Nature, vol. 16(1), pages 1-17, December.
    9. Pooja Middha & Rohit Thummalapalli & Michael J. Betti & Lydia Yao & Zoe Quandt & Karmugi Balaratnam & Cosmin A. Bejan & Eduardo Cardenas & Christina J. Falcon & David M. Faleck & Matthew A. Gubens & S, 2024. "Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    10. Jianting Long & Xihe Chen & Mian He & Shudan Ou & Yunhe Zhao & Qingjia Yan & Minjun Ma & Jingyu Chen & Xuping Qin & Xiangjun Zhou & Junjun Chu & Yanyan Han, 2024. "HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice," Nature Communications, Nature, vol. 15(1), pages 1-13, December.

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:ejmed0:v:2:y:2020:i:5:id:40482. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support (email available below). General contact details of provider: https://eu-opensci.org/index.php/ejmed .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.